A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-to-Severe Plaque Psoriasis (NCT06550076)
TAK-279-PsO-3003
This trial is No longer recruiting
Registration number NCT06550076
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Johannes S Kern
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR